Cordavis is a wholly owned subsidiary of CVS Health® that works directly with manufacturers to bring biosimilar products to the U.S. market. Cordavis works with manufacturers to co-produce FDA-approved, high-quality products that are affordable and easy for patients to use. By focusing on these objectives, Cordavis aims to support a vibrant and competitive biosimilar market in the U.S. and drive sustainable cost savings for consumers well into the future.
Company Details
- Employees
- 46
- Founded
- 2023
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.cordavis.com/
- Keywords
- Biosimilars.
Cordavis Questions
Cordavis's website is https://www.cordavis.com/
Cordavis's LinkedIn profile is https://www.linkedin.com/company/cordavis
Cordavis has
46 employees.
View email and phone details for 46
employees at Cordavis.
Cordavis's industry is
Pharmaceutical Manufacturing
Cordavis's top competitors are
Optum,
Cvs Health,
Quallent Pharmaceuticals Health, Llc,
Express Scripts Pharmacy Benefit Services,
Mckesson,
Astrazeneca,
Alexion Pharmaceuticals, Inc.,
Icon Plc,
Setanta Life Sciences,
Aetna, A Cvs Health Company.
Cordavis's categories are Pharmaceutical Manufacturing
Cordavis's founding year is 2023
